Formulierung für Anti-ALPHA4BETA7-Antikörper
Anmelder: Millennium Pharmaceuticals, Inc. 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4775272
- Anmeldetag
- 2. Mai 2012
- Veröffentlichung
- 15. Juli 2026
- Rechtsraum
- EP
- IPC
- A61P37/02
Abstract
Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Anmelder
- Firma
- Millennium Pharmaceuticals, Inc.
- Land
- 🇺🇸 USA
US-amerikanisches Pharmaunternehmen mit Sitz in Cambridge, Massachusetts, spezialisiert auf Onkologiepräparate, seit 2008 Tochtergesellschaft von Takeda.
882 Patente in unserer Datenbank
Fachgebiete
Vertreten von
-
Hoffmann Eitle
Hoffmann Eitle · München